News Beam Therapeutics Inc.

Stocks

BEAM

US07373V1052

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 18:59:30 12/06/2026 BST			5-day change	1st Jan Change
28.95 ^USD	-1.56%		-0.37%	+5.66%

05-25	Beam Therapeutics Inc. Presents at RBC Capital Markets Global Healthcare Conference 2026, May-20-2026 10:30 AM
05-18	Beam Therapeutics Inc. Presents Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency At American Thoracic Society International Conference	CI

All News

Mentions Relevance

05-25	Beam Therapeutics Inc. Presents at RBC Capital Markets Global Healthcare Conference 2026, May-20-2026 10:30 AM
05-18	Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference	GL
05-18	Beam Therapeutics Inc. Presents Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency At American Thoracic Society International Conference	CI
05-13	Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference	GL
05-12	Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026	GL
05-07	Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Earnings Flash (BEAM) Beam Therapeutics Inc. Reports Q1 Revenue $31.7M, vs. FactSet Est of $11.0M	MT
05-07	Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates	GL
04-02	Beam Therapeutics Insider Sold Shares Worth $1,128,315, According to a Recent SEC Filing	MT
04-01	Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine	GL
04-01	Beam Therapeutics Publishes Beacon Phase 1/2 Data for Risto-Cel in Patients with Sickle Cell Disease	CI
03-25	Beam Therapeutics Inc. - Special Call
03-25	Beam Therapeutics Says It Advances BEAM-302 to Pivotal Stage With 60 mg Dose Selection	MT
03-25	Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency	CI
03-25	Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development	GL
03-05	Beam Therapeutics Inc. Terminates License Agreement with Bio Palette Co., Ltd	CI
02-25	RBC Capital Adjusts Beam Therapeutics Price Target to $26 From $22, Maintains Sector Perform - Speculative Risk Rating	MT
02-24	Beam Therapeutics Inc., Q4 2025 Earnings Call, Feb 24, 2026
02-24	Beam Therapeutics Shares Rise After Swinging to Q4 Adjusted Earnings	MT
02-24	Beam Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-24	Beam Therapeutics Inc. announced that it expects to receive $500 million in funding	CI
02-24	Wedbush Raises Beam Therapeutics Price Target to $65 From $57, Maintains Outperform Rating	MT
02-24	Beam Therapeutics Inc. Announces $500 Million Strategic Financing Facility with Sixth Street	CI
02-24	Beam Therapeutics Secures Up to $500 Million Sixth Street Financing	MT
02-24	Beam Therapeutics Swings to Q4 Adjusted Earnings, Revenue Rises -- Shares Up Pre-Bell	MT